Key Takeaways
- • Enveda Biosciences raised $311 million in Series E funding led by Catalio Capital Management, valuing the Colorado-based AI drug discovery company at $2 billion and bringing total capital raised to over $530 million.
- • The company has advanced three AI-designed drug candidates into human clinical testing, including ENV-294 for atopic dermatitis and asthma (currently in Phase 2) and ENV-308 positioned as an obesity treatment, with 17 additional programs under evaluation.
- • Enveda's proprietary platform uses artificial intelligence to identify bioactive molecules from plants and microbes, predict their molecular structure and function, and rank candidates by drug potential—a methodology CEO Viswa Colluru argues generates first-in-class mechanisms that drive patient outcomes and venture returns.
- • The $311 million Series E round matches funding levels achieved in some of the biotech sector's larger IPOs this year, signaling substantial investor confidence in AI-driven drug discovery as a viable alternative to traditional development pipelines.
- • ENV-294 demonstrated early clinical efficacy as a "molecular glue" pill for reducing eczema symptoms in atopic dermatitis patients unresponsive to existing treatments like Dupixent, representing a potential differentiated therapeutic approach in immunological diseases.
Summary
Enveda Biosciences, a Colorado-based artificial intelligence specialist focused on drug discovery from natural organisms, announced a $311 million Series E funding round on September 23, 2026, led by Catalio Capital Management. The financing values the company at $2 billion and represents a significant capital deployment in the AI-driven biotech sector. Combined with prior funding, Enveda has now raised over $530 million since inception, positioning it among well-capitalized early-stage biotechnology companies.
The company's platform identifies bioactive molecules from plants and microbes using artificial intelligence, then applies computational methods to predict molecular structure and biological function. Enveda's chemists subsequently synthesize the most promising candidates into clinical-stage drug prospects. This nature-derived, AI-enabled discovery model differs from conventional high-throughput screening and rational drug design, with CEO and founder Viswa Colluru emphasizing that the approach yields first-in-class mechanisms capable of shifting therapeutic paradigms. The company is currently evaluating 17 distinct programs emerging from this research methodology.
Three AI-discovered candidates have progressed to human clinical testing. ENV-294, a "molecular glue" compound administered as an oral medication, demonstrated potential to reduce eczema symptoms in Phase 1 trials for atopic dermatitis patients who have failed approved biologics such as Dupixent. The program has advanced to Phase 2 trials in both eczema and asthma indications. ENV-308, described by Enveda as a "pill designed from the chemistry of exercise," targets obesity and represents a second major pipeline asset in human trials. Phase 1 data for both programs were disclosed earlier in 2026.
The Series E financing will fund continued clinical development of these programs and expansion of Enveda's pipeline. The $311 million raise aligns with funding totals achieved in several biotech sector initial public offerings executed during 2026, indicating that institutional investors view AI-assisted drug discovery as a defensible mechanism for generating novel therapeutic entities. Enveda's valuation at $2 billion reflects market confidence in both its proprietary technology platform and its ability to translate AI-identified molecules into clinically viable drug candidates across multiple therapeutic areas.
The company's platform identifies bioactive molecules from plants and microbes using artificial intelligence, then applies computational methods to predict molecular structure and biological function. Enveda's chemists subsequently synthesize the most promising candidates into clinical-stage drug prospects. This nature-derived, AI-enabled discovery model differs from conventional high-throughput screening and rational drug design, with CEO and founder Viswa Colluru emphasizing that the approach yields first-in-class mechanisms capable of shifting therapeutic paradigms. The company is currently evaluating 17 distinct programs emerging from this research methodology.
Three AI-discovered candidates have progressed to human clinical testing. ENV-294, a "molecular glue" compound administered as an oral medication, demonstrated potential to reduce eczema symptoms in Phase 1 trials for atopic dermatitis patients who have failed approved biologics such as Dupixent. The program has advanced to Phase 2 trials in both eczema and asthma indications. ENV-308, described by Enveda as a "pill designed from the chemistry of exercise," targets obesity and represents a second major pipeline asset in human trials. Phase 1 data for both programs were disclosed earlier in 2026.
The Series E financing will fund continued clinical development of these programs and expansion of Enveda's pipeline. The $311 million raise aligns with funding totals achieved in several biotech sector initial public offerings executed during 2026, indicating that institutional investors view AI-assisted drug discovery as a defensible mechanism for generating novel therapeutic entities. Enveda's valuation at $2 billion reflects market confidence in both its proprietary technology platform and its ability to translate AI-identified molecules into clinically viable drug candidates across multiple therapeutic areas.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.